No Data
No Data
Central Bank's major announcement! Reserve ratio cut, interest rate cut, officially launching share buyback and shareholding refinancing.
Pan Gongsheng stated that it is expected to carefully assess the market liquidity situation before the end of the year, and opportunistically further lower the deposit reserve ratio by 0.25-0.5 percentage points; reduce the open market 7-day reverse repurchase operation rate by 0.2 percentage points.
Hong Kong stocks midday review | The three major indices collectively rebounded! The technology index rose by over 1%; the technology, internet, semiconductors, and brokerage sectors led the gains, with Xiaomi and China Merchants rising by about 4%, while
Network technology stocks rose across the board, SenseTime-W rose by 4.00%, Xiaomi Group-W rose by 3.96%; shares of real estate developers mostly declined, Sunac fell by 21.10%, China Vanke fell by 10.65%; stocks of property services and management trended lower, Evergr Services fell by 6.74%, Wanyuwang fell by 5.59%.
HUTCHMED Shares Are Trading Higher After the Company Announced High-level Results From the SAVANNAH Phase II Trial.
Hutchmed Says Combination Lung Cancer Therapy Shows Efficacy in Phase 2 Study
HUTCHMED Reports TAGRISSO Plus ORPATHYS Showed Clinically Meaningful Responses In Lung Cancer Patients With High MET Overexpression Or Amplification In The SAVANNAH Phase II Trial
hutchmed (china) Tyvyt and Sulanda combined therapy shows clinical significance in remission rate.
hutchmed (china) (00013.HK) announced that the SAVANNAH Phase II study has achieved positive preliminary results. The combination therapy of Tagrisso (osimertinib) and Orpathys (savolitinib) in patients with advanced non-small cell lung cancer who have previously progressed after Tagrisso treatment, accompanied by high levels of Met overexpression and/or amplification (defined as IHC90+ and/or FISH10+) of Epidermal Growth Factor Receptor (EGFR).